Nicola Campbell Joins Sofinnova Ventures as a Life Science Partner

Aug 17, 2004, 01:00 ET from Sofinnova Ventures

    SAN FRANCISCO, Aug. 17 /PRNewswire/ -- Sofinnova Ventures, a San Francisco
 venture firm investing in early-stage life science and information technology
 companies, announced today that Nicola Campbell, Ph.D. has joined the firm as
 a life science partner.  Her investment focus will be on early-stage
 investment opportunities in the sectors of drug discovery and pharmaceutical
 and biologic development.
     Most recently, Campbell was a principal with BA Venture Partners, where
 she focused on mid-stage investment opportunities in drug discovery and
 product-based companies. She joined BAVP from Burrill & Co, a life science
 merchant banking firm focusing on biotechnology venture capital. Prior to
 joining the venture community, Campbell spent four years at Genentech in both
 business development and scientific roles. She developed strategic
 partnerships with Actelion and Gene Logic, among others, and was a member of
 the Cardiovascular Therapeutic Area Team responsible for the strategic vision
 of that franchise. She initially joined Genentech as an immunologist in the
 research department.
     "I have known Mike Powell and Jim Healy for years, and worked with them on
 numerous projects and deals," said Campbell. "Sofinnova has a terrific team,
 all around, a strong LP base, and continues to strengthen its reputation
 across communities. I'm really delighted to be part of their team."
     "Our collaborative history with Nicola makes her a natural fit for our
 team," commented Jim Healy, M.D., Ph.D., managing director, Sofinnova
 Ventures. "And her background makes her a natural asset to our team. She has
 an excellent track record as a venture capitalist, and as a business
 development executive and clinical immunologist with Genentech. She has a
 well-rounded skill set and a terrific network across the industry. She's a
 real catch."
     Campbell received her Ph.D. in Molecular and Cellular Immunology from
 Mount Sinai Medical Center, during which she was a recipient of the American
 Gastroenterology Association's Outstanding Research Award. She completed her
 MS in Medical Sciences from the Mount Sinai School of Medicine, and received
 her BS in Human Biology from the University of Guelph in Ontario, Canada,
 where she was awarded the Dean's Scholarship for Academic Excellence.
     About Sofinnova Ventures
     San Francisco-based Sofinnova Ventures, founded in 1974, has $600 million
 under management. The firm emphasizes a diversified investment strategy
 through financing seed and early-stage companies in the life science and
 information technology sectors. Historically, Sofinnova has been associated
 with leading companies such as Biogen, Collagen, Genentech, Printronix, Tandem
 Computers and Tandon. More recently, Sofinnova invested in Actelion, Aviron,
 Element-14 (Broadcom), InterMune, Millennium Pharmaceuticals,,
 Premisys, Seattle Genetics and Tumbleweed Communications. For more
 information, visit

SOURCE Sofinnova Ventures